These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 7780090)
21. Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success. Cowie RL; Langton ME; Escreet BC S Afr Med J; 1985 Dec; 68(12):879-80. PubMed ID: 4071345 [TBL] [Abstract][Full Text] [Related]
22. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Ahn CH; Ahn SS; Anderson RA; Murphy DT; Mammo A Am Rev Respir Dis; 1986 Sep; 134(3):438-41. PubMed ID: 3530069 [TBL] [Abstract][Full Text] [Related]
23. Present status of chemotherapy for tuberculosis. Grosset JH Rev Infect Dis; 1989; 11 Suppl 2():S347-52. PubMed ID: 2652251 [TBL] [Abstract][Full Text] [Related]
24. Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Levine B; Chaisson RE Ann Intern Med; 1991 May; 114(10):861-8. PubMed ID: 1673053 [TBL] [Abstract][Full Text] [Related]
25. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis. Al Jarad N; Demertzis P; Jones DJ; Barnes NC; Rudd RM; Gaya H; Wedzicha JA; Hughes DT; Empey DW Thorax; 1996 Feb; 51(2):137-9. PubMed ID: 8711643 [TBL] [Abstract][Full Text] [Related]
26. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Kohno S; Koga H; Kaku M; Maesaki S; Hara K Chest; 1992 Dec; 102(6):1815-8. PubMed ID: 1446494 [TBL] [Abstract][Full Text] [Related]
27. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach. Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R; Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298 [TBL] [Abstract][Full Text] [Related]
28. Pulmonary Infection Caused by Mycobacterium shinjukuense. Oshima K; Yokouchi H; Minemura H; Saito J; Tanino Y; Munakata M Ann Am Thorac Soc; 2015 Jun; 12(6):958-9. PubMed ID: 26075560 [No Abstract] [Full Text] [Related]
29. Short-course chemotherapy for mycobacteriosis kansasii? Schraufnagel DE; Leech JA; Schraufnagel MN; Pollak B Can Med Assoc J; 1984 Jan; 130(1):34-8. PubMed ID: 6418368 [TBL] [Abstract][Full Text] [Related]
30. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029 [TBL] [Abstract][Full Text] [Related]
31. [Acquired rifampicin resistance during M. kansasii infection in a patient with AIDS]. Dautzenberg B; Antoun F; Truffot C Rev Mal Respir; 1992; 9(4):464-6. PubMed ID: 1509191 [TBL] [Abstract][Full Text] [Related]
32. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study. Am Rev Respir Dis; 1984 Jun; 129(6):921-8. PubMed ID: 6375490 [TBL] [Abstract][Full Text] [Related]
33. [The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance]. Tan S; Ding X; Tan Y; Cai X; Li Y Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):915-8. PubMed ID: 25609129 [TBL] [Abstract][Full Text] [Related]
34. [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability]. Wada M; Yoshiyama T; Ogata H; Ito K; Mizutani S; Sugita H Kekkaku; 1999 Apr; 74(4):353-60. PubMed ID: 10355221 [TBL] [Abstract][Full Text] [Related]
35. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]
36. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial. Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240 [TBL] [Abstract][Full Text] [Related]
37. Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis. Bai KJ; Yu MC; Suo J; Chiang CY; Chiang IH; Lin TP; Luh KT J Formos Med Assoc; 1998 Apr; 97(4):278-82. PubMed ID: 9585680 [TBL] [Abstract][Full Text] [Related]
38. Pulmonary disease caused by Mycobacterium xenopi in an Australian man. Woolcock WJ; Dawson DJ Med J Aust; 1979 Aug; 2(4):175-7. PubMed ID: 514123 [TBL] [Abstract][Full Text] [Related]
39. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment]. Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263 [TBL] [Abstract][Full Text] [Related]
40. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM; Goldberg SV Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]